SOURCE: BioMedReports


January 26, 2010 14:54 ET

IR Biosciences' ImmuneRegen (OTCBB: IRBS) Getting Attention for Its Adult Stem Cell Active Compound

LOS ANGELES, CA--(Marketwire - January 26, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that unlike most newer biotechs of this size and experience in the market, IR Biosciences' ImmuneRegen (OTCBB: IRBS) seems to be gathering quite a bit of attention from places like the NIH, the National Cancer Institute, BARDA (Biomedical Advanced Research and Development Authority), and the armed forces.

ImmuneRegen's development candidate Homspera® appears to be the focus of their attention and it happens to be that the compound has several broad-reaching applications.

Study results have shown its ability to regenerate and strengthen the immune system and enhance wound healing, thereby providing possible treatments for acute radiation exposure, infectious diseases, vaccine adjuvancy, and chemical exposures.

The compound has been modulating the immune system. How it plays a role for various indications has increased the company's confidence in its candidacy for various large market opportunities as well as a rumored and yet to be publicly announced partnership with one integrated pharmaceutical industry player as they get further into clinical studies. That same company has a high level of interest (as do other entities) in purchasing the company's compound as a therapy for cancer -- melanoma specifically.

A complete report on the company with quotes from its CEO Michael Wilhelm is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556